UK markets open in 7 hours 26 minutes
NIKKEI 225
38,460.08 +907.92 (+2.42%) HANG SENG
17,201.27 +372.34 (+2.21%) CRUDE OIL
82.80 -0.01 (-0.01%) GOLD FUTURES
2,328.40 -10.00 (-0.43%) DOW
38,460.92 -42.77 (-0.11%) Bitcoin GBP
51,461.52 -1,831.19 (-3.44%)
Corcept Therapeutics Incorporated (0I3Q.L)
LSE - LSE Delayed price. Currency in USD
Add to watchlist
At close: 03:27PM BST
| Previous close | 24.01 |
| Open | 22.31 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 22.19 - 22.34 |
| 52-week range | 20.76 - 34.12 |
| Volume | |
| Avg. volume | 2,318 |
| Market cap | 22.191M |
| Beta (5Y monthly) | 0.48 |
| PE ratio (TTM) | 0.24 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Corcept (CORT) Posts Positive Data From Cushing's Syndrome Study
Corcept (CORT) reports positive data from the open-label portion of the phase III GRACE study evaluating relacorilant for treating patients with Cushing's syndrome.
- Zacks
Corcept (CORT) Upgraded to Strong Buy: Here's What You Should Know
Corcept (CORT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
- Zacks
Corcept (CORT) Completes Enrollment in Phase II ALS Study
The phase II DAZALS study is evaluating Corcept's (CORT) dazucorilant for treating patients with amyotrophic lateral sclerosis. Enrollment in the study is already complete.
© 2024 Yahoo. All rights reserved.